Open Beta
TREN
MetriLume
TREN

US marketsAMLX

SEC-sourced researchBeta

AMLX

Amylyx Pharmaceuticals, Inc.

Company comparison ↗

Data passport

CIK
0001658551
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 7, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 87,371,000.0000 USD; December 2025: 0.0000 USD87.4M USD0 USD0December 2024December 2025
AMLX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202487,371,000.0000Mar 3, 2026
December 20250.0000Mar 3, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20250.0000-144,735,000.0000-123,343,000.0000332,645,000.000027,386,000.0000Mar 3, 2026
December 202487,371,000.0000-301,743,000.0000-167,647,000.0000193,634,000.000028,869,000.0000Mar 3, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

58/100
Profitability—
Growth0
Balance sheet92
Cash generation—
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$0Jan 1, 2025 – Dec 31, 2025Mar 3, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$87.37MJan 1, 2024 – Dec 31, 2024Mar 3, 202610-K
Net incomeNetIncomeLoss-$144.74MJan 1, 2025 – Dec 31, 2025Mar 3, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$123.34MJan 1, 2025 – Dec 31, 2025Mar 3, 202610-K
Total assetsAssets$332.65MDec 31, 2025Mar 3, 202610-K
Total liabilitiesLiabilities$27.39MDec 31, 2025Mar 3, 202610-K

New filings

Explore methodology ↗